The company is recalling certain lots of its insulin patch pumps after finding a small tear in the internal tubing may cause ...

A tear in the tubing may prevent users from getting full insulin doses. So far 18 people have reported serious issues related ...

Insulet estimates that the pods involved in this correction represent approximately 1.5% of annual production globally.

Insulet Corporation (NASDAQ: PODD) ("Insulet" or the "Company") today initiated a voluntary Medical Device Correction for ...

( NewsNation) — Type-1 Diabetes insulin pods have been recalled over a manufacturing issue, according to the U.S. Food and ...

Insulet has begun recalling specific lots of its Omnipod 5 insulin pumps in the U.S. | The diabetes tech company said it is aware of 18 cases of serious complications related to the under-delivery of ...

Earlier this week, Insulet announced a voluntary medical device correction and recall for specific Omnipod 5 pod lots in the US after detecting a manufacturing defect that can cause insulin ...

Insulet expects to incur up to $40 million in costs associated with the correction in 2026 and does not anticipate updating its previously issued guidance for the year, according to a filing with the ...

Insulet Corp. PODD shares are down during Friday’s premarket session following the company’s announcement of a voluntary Medical Device Correction for certain lots of Omnipod 5 Pods. Manufacturing ...

Patients with type 2 diabetes who used the Omnipod 5 had lower A1C after 8 weeks. Those who had been using multiple daily injections achieved the greatest benefits in reduced hypoglycemia and reduced ...

Insulin pump-maker Insulet has scored FDA 510(k) clearance for its Omnipod 5 Automated Insulin Delivery System for people ages 6 and up with Type 1 diabetes. The pump integrates with the Dexcom G6 ...

The clearance was based on data from a single-arm multicenter clinical trial that evaluated the Omnipod 5 system in 80 children aged 2 to 5.9 years with type 1 diabetes. The Food and Drug ...